{"id":"NCT00993824","sponsor":"HealthPartners Institute","briefTitle":"Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes","officialTitle":"Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-09","primaryCompletion":"2011-09","completion":"2011-09","firstPosted":"2009-10-14","resultsPosted":"2014-06-17","lastUpdate":"2015-11-30"},"enrollment":21,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"colesevelam HCl","otherNames":["Welchol"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Welchol then Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Placebo then Welchol","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo. The CGM data will determine the effect on glucose control of adding Welchol to an anti-diabetic medication regimen.","primaryOutcome":{"measure":"Total Norm AUC Average by Group (Normalized)","timeFrame":"2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.","effectByArm":[{"arm":"Welchol Then Placebo","deltaMin":150.8,"sd":10.8},{"arm":"Placebo Then Welchol","deltaMin":175.9,"sd":29.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["18852398","18473688","18663165","19132850","17379048"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":[]}}